Pyridostigmine-induced coronary artery spasm in early-onset myasthenia gravis: a case presentation and review of the literature

BMJ Case Rep. 2022 Sep 14;15(9):e249819. doi: 10.1136/bcr-2022-249819.

Abstract

We present a case of pyridostigmine-induced coronary artery spasm in a woman with early-onset myasthenia gravis (MG) who suffered from acute chest discomfort a few days after pyridostigmine dose up-titration. Twelve-lead ECG demonstrated ST-segment elevation in inferior limb leads together with sinus arrest. Sublingual nitrate was immediately given, which rapidly relieved her symptoms concomitantly with the resolution of abnormal ECG findings. Coronary angiography showed normal coronary arteries reflecting the transient nature of the disease. A small dose of pyridostigmine was rechallenged under close monitoring in the coronary care unit and reproduced her chest discomfort. After the substitution of pyridostigmine with immunosuppressive agents and prescription of long-acting nitrate, she had no recurrence of chest discomfort, as well as well-controlled MG symptoms.

Keywords: Arrhythmias; Ischaemic heart disease; Neurology (drugs and medicines); Neuromuscular disease; Unwanted effects / adverse reactions.

Publication types

  • Case Reports

MeSH terms

  • Coronary Vasospasm* / chemically induced
  • Coronary Vasospasm* / diagnosis
  • Coronary Vasospasm* / drug therapy
  • Coronary Vessels
  • Female
  • Humans
  • Myasthenia Gravis* / chemically induced
  • Myasthenia Gravis* / complications
  • Myasthenia Gravis* / diagnosis
  • Nitrates
  • Pyridostigmine Bromide / therapeutic use
  • Spasm

Substances

  • Nitrates
  • Pyridostigmine Bromide